Polyclonal Antibodies Market Outlook:
Polyclonal Antibodies Market size was valued at USD 1.72 billion in 2025 and is likely to cross USD 2.88 billion by 2035, registering more than 5.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of polyclonal antibodies is assessed at USD 1.8 billion.
The market expansion is due to the projected need for therapeutic applications, as polyclonal antibodies find extensive use in therapeutic applications, notably in the development of antivenom and immunoglobulin therapies, which can help in preventing hemolytic disease in newborns while modifying inflammatory reactions.
According to a report, about 25% of newborns suffer from hemolytic disease of the newborns (HDN), which requires transfusion. Due to this, this industry is expected to witness a substantial growth rate in the forecasted years.
In addition, adopting polyclonal antibodies is particularly important in cases where the multifaceted nature of diseases necessitates a comprehensive immune response. For instance, in antivenom therapy, polyclonal antibodies are harnessed to neutralize the venom components of various snake species effectively.
